|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPHOSPH10 |
Gene summary for MPHOSPH10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPHOSPH10 | Gene ID | 10199 |
| Gene name | M-phase phosphoprotein 10 | |
| Gene Alias | CT90 | |
| Cytomap | 2p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | O00566 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10199 | MPHOSPH10 | LZE2T | Human | Esophagus | ESCC | 1.49e-02 | 8.29e-01 | 0.082 |
| 10199 | MPHOSPH10 | LZE4T | Human | Esophagus | ESCC | 6.52e-22 | 6.48e-01 | 0.0811 |
| 10199 | MPHOSPH10 | LZE5T | Human | Esophagus | ESCC | 1.63e-02 | 1.72e-01 | 0.0514 |
| 10199 | MPHOSPH10 | LZE7T | Human | Esophagus | ESCC | 9.71e-09 | 4.27e-01 | 0.0667 |
| 10199 | MPHOSPH10 | LZE8T | Human | Esophagus | ESCC | 2.02e-06 | 1.39e-01 | 0.067 |
| 10199 | MPHOSPH10 | LZE20T | Human | Esophagus | ESCC | 1.36e-02 | 7.16e-02 | 0.0662 |
| 10199 | MPHOSPH10 | LZE22T | Human | Esophagus | ESCC | 4.44e-04 | 3.78e-01 | 0.068 |
| 10199 | MPHOSPH10 | LZE24T | Human | Esophagus | ESCC | 2.98e-11 | 2.55e-01 | 0.0596 |
| 10199 | MPHOSPH10 | LZE6T | Human | Esophagus | ESCC | 1.82e-02 | 1.30e-01 | 0.0845 |
| 10199 | MPHOSPH10 | P1T-E | Human | Esophagus | ESCC | 1.87e-15 | 8.53e-01 | 0.0875 |
| 10199 | MPHOSPH10 | P2T-E | Human | Esophagus | ESCC | 1.45e-41 | 7.32e-01 | 0.1177 |
| 10199 | MPHOSPH10 | P4T-E | Human | Esophagus | ESCC | 6.93e-41 | 9.51e-01 | 0.1323 |
| 10199 | MPHOSPH10 | P5T-E | Human | Esophagus | ESCC | 1.71e-38 | 7.05e-01 | 0.1327 |
| 10199 | MPHOSPH10 | P8T-E | Human | Esophagus | ESCC | 2.32e-28 | 3.37e-01 | 0.0889 |
| 10199 | MPHOSPH10 | P9T-E | Human | Esophagus | ESCC | 4.12e-19 | 4.51e-01 | 0.1131 |
| 10199 | MPHOSPH10 | P10T-E | Human | Esophagus | ESCC | 1.18e-49 | 8.12e-01 | 0.116 |
| 10199 | MPHOSPH10 | P11T-E | Human | Esophagus | ESCC | 1.21e-20 | 6.51e-01 | 0.1426 |
| 10199 | MPHOSPH10 | P12T-E | Human | Esophagus | ESCC | 8.60e-39 | 6.26e-01 | 0.1122 |
| 10199 | MPHOSPH10 | P15T-E | Human | Esophagus | ESCC | 7.25e-31 | 7.08e-01 | 0.1149 |
| 10199 | MPHOSPH10 | P16T-E | Human | Esophagus | ESCC | 2.88e-41 | 8.36e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000636412 | Liver | Cirrhotic | rRNA processing | 115/4634 | 225/18723 | 1.12e-17 | 1.64e-15 | 115 |
| GO:00160724 | Liver | Cirrhotic | rRNA metabolic process | 119/4634 | 236/18723 | 1.19e-17 | 1.70e-15 | 119 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPHOSPH10 | SNV | Missense_Mutation | c.1847N>T | p.Ser616Leu | p.S616L | O00566 | protein_coding | tolerated(0.43) | benign(0.011) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPHOSPH10 | SNV | Missense_Mutation | c.331G>A | p.Glu111Lys | p.E111K | O00566 | protein_coding | tolerated(0.29) | possibly_damaging(0.883) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MPHOSPH10 | SNV | Missense_Mutation | c.567N>C | p.Lys189Asn | p.K189N | O00566 | protein_coding | tolerated(0.12) | benign(0.129) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| MPHOSPH10 | SNV | Missense_Mutation | rs746074531 | c.1460A>C | p.Glu487Ala | p.E487A | O00566 | protein_coding | deleterious(0.02) | possibly_damaging(0.906) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| MPHOSPH10 | SNV | Missense_Mutation | c.839C>A | p.Thr280Lys | p.T280K | O00566 | protein_coding | tolerated(0.86) | benign(0.061) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD | |
| MPHOSPH10 | insertion | Frame_Shift_Ins | novel | c.1793_1794insCTTACACAGTAATAATGGTTTCTGCCAGGTGCTCATCTTCCTGGCTG | p.Glu600HisfsTer21 | p.E600Hfs*21 | O00566 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| MPHOSPH10 | insertion | Frame_Shift_Ins | novel | c.1362_1363insA | p.Arg457AlafsTer7 | p.R457Afs*7 | O00566 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MPHOSPH10 | insertion | In_Frame_Ins | novel | c.1536_1537insAAA | p.Asn512_Phe513insLys | p.N512_F513insK | O00566 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MPHOSPH10 | insertion | In_Frame_Ins | novel | c.1537_1538insACATGTACATGGCACTATTAACAG | p.Phe513delinsTyrMetTyrMetAlaLeuLeuThrVal | p.F513delinsYMYMALLTV | O00566 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MPHOSPH10 | SNV | Missense_Mutation | novel | c.377A>G | p.Asp126Gly | p.D126G | O00566 | protein_coding | tolerated(0.74) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |